{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-083250","form_type":"8-K","ticker":null,"cik":"0001641640","company_name":"Nabriva Therapeutics plc","filed_at":"2023-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.654626+00:00","generated_at":"2026-06-13T04:14:51.475512+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Nabriva receives Nasdaq delisting notice; trading to suspend Aug 1, 2023","bullets":["Stockholders' equity deficit of $(4,357,000) as of March 31, 2023 fails $2.5M minimum under Rule 5550(b)(1).","Nasdaq will suspend trading at open on August 1, 2023; Company will not appeal.","Ordinary shares may become eligible for Pink Open Market quotation, but no assurances given."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-083250","json":"https://secwatch.observer/filing/0001104659-23-083250.json","markdown":"https://secwatch.observer/filing/0001104659-23-083250.md","text":"https://secwatch.observer/filing/0001104659-23-083250.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641640/000110465923083250/0001104659-23-083250-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641640/000110465923083250/tm2321842d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T04:14:51.475512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7b7dae6390c00d92956ef5ba541fe9f3ae950be","claim":"Nabriva Therapeutics plc received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"July 21, 2023, Nabriva Therapeutics plc (the “Company”) received a delisting determination letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”). The Determination Letter indicated that, based on (i) the Company’s continued non-compliance with the Nasdaq Capital Market’s requirement to have a minimum stockholders’ equity of $2,500,000 under Nasdaq Listing Rule 5550(b)(1) (the “Rule”) and (ii) the Company’s confirmation that it did not intend to submit a plan to regain compliance with the Rule, the Company’s ordinary shares, nominal value $0.01 per share (the “Ordinary","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641640/000110465923083250/0001104659-23-083250-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}